Fungal Infection Management Technology for effectively encapsulating Amphotericin B – Indian Patent 336184 Granted – Ready for Licensing

Fungal Infection Management Technology for effectively encapsulating Amphotericin B – Indian Patent 336184 Granted – Ready for Licensing

My lab has patented a technology (Indian patent 336184 granted) for effectively encapsulating Amphotericin B in systematically optimised (using QbD) solid lipid nanoparticles (AmB occurring as discrete monomeric form) with ~1500% increase in bioavailability; 3.2 times higher LD50, no repeat dose toxicity observed in rats (OECD guidelines); 20 times lower MIC against Candida albicans; better (~10 times) uptake into host macrophages and Candida albicans.

Inviting Offers, please leave your contact details in the form below.

by Dr. Indu Pal Kaur | Contact vendor

 

Some FAQ’s

1] Is there any human clinical trial data on its bioavailability level in the blood, half-life, and any significant improvement with its efficacy for this drug?

Response: I have all pre- clinical data on efficacy, safety, stability and in vitro cellular uptake and antifungal efficacy.

2] Wanted to understand and read more about the concept- Is it feasible as an end product for human application, namely the stability of the drug and treatment? If you have any publications on this topic can you please share them?

Response: Please fill the form in with your details, shall revert on your personal message / email.

3] Is it an oral formulation?

Response: No it is evaluated as an IV injection but we can do studies for oral bioavailability also.

 

 

Spread the love

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Need Help? Contact Us Leave Feedback

Category:

Tags: , , , , , , ,